Literature DB >> 10836145

Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators.

J C Corton1, S P Anderson, A Stauber.   

Abstract

Peroxisome proliferators (PPs) are a large class of structurally dissimilar chemicals that have diverse effects in rodents and humans. Most, if not all, of the diverse effects of PPs are mediated by three members of the nuclear receptor superfamily called peroxisome proliferator-activated receptors (PPARs). In this review, we define the molecular mechanisms of PPs, including PPAR binding specificity, alteration of gene expression through binding to DNA response elements, and cross talk with other signaling pathways. We discuss the roles of PPARs in growth promotion in rodent hepatocarcinogenesis and potential therapeutic effects, including suppression of cancer growth and inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836145     DOI: 10.1146/annurev.pharmtox.40.1.491

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  72 in total

1.  Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.

Authors:  Bernard Pirard
Journal:  J Comput Aided Mol Des       Date:  2003-11       Impact factor: 3.686

Review 2.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

3.  Association of FURIN and ZPR1 polymorphisms with metabolic syndrome.

Authors:  Chikara Ueyama; Hideki Horibe; Yuichiro Yamase; Tetsuo Fujimaki; Mitsutoshi Oguri; Kimihiko Kato; Masazumi Arai; Sachiro Watanabe; Toyoaki Murohara; Yoshiji Yamada
Journal:  Biomed Rep       Date:  2015-06-29

4.  Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1.

Authors:  Raquel Grau; Carmen Punzón; Manuel Fresno; Miguel A Iñiguez
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

5.  Therapeutic Implications of PPARgamma in Human Osteosarcoma.

Authors:  Eric R Wagner; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Wenli Zhang; Qiong Shi; Qing Luo; Xiaoji Luo; Bo Liu; Jinyong Luo; Farbod Rastegar; Connie J He; Yawen Hu; Barrett Boody; Hue H Luu; Tong-Chuan He; Zhong-Liang Deng; Rex C Haydon
Journal:  PPAR Res       Date:  2010-02-16       Impact factor: 4.964

6.  Influence of peroxisome proliferator-activated receptor (PPAR)gamma Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese.

Authors:  Tomomitsu Tahara; Tomiyasu Arisawa; Tomoyuki Shibata; Masakatsu Nakamura; Fangyu Wang; Naoko Maruyama; Yoshio Kamiya; Masahiko Nakamura; Hiroshi Fujita; Mitsuo Nagasaka; Masami Iwata; Kazuya Takahama; Makoto Watanabe; Ichiro Hirata; Hiroshi Nakano
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

7.  Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures.

Authors:  Manjeet K Paintlia; Ajaib S Paintlia; Mushfiquddin Khan; Inderjit Singh; Avtar K Singh
Journal:  J Neurochem       Date:  2008-01-12       Impact factor: 5.372

Review 8.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

9.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

10.  Peroxisome proliferator-activated receptors in diabetic nephropathy.

Authors:  Shinji Kume; Takashi Uzu; Keiji Isshiki; Daisuke Koya
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.